GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Return-on-Tangible-Asset

INVA (Innoviva) Return-on-Tangible-Asset : -17.67% (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Innoviva's annualized Net Income for the quarter that ended in Mar. 2025 was $-186.3 Mil. Innoviva's average total tangible assets for the quarter that ended in Mar. 2025 was $1,054.6 Mil. Therefore, Innoviva's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -17.67%.

The historical rank and industry rank for Innoviva's Return-on-Tangible-Asset or its related term are showing as below:

INVA' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -5.82   Med: 23.75   Max: 86.3
Current: -5.82

During the past 13 years, Innoviva's highest Return-on-Tangible-Asset was 86.30%. The lowest was -5.82%. And the median was 23.75%.

INVA's Return-on-Tangible-Asset is ranked better than
75.25% of 1499 companies
in the Biotechnology industry
Industry Median: -36.14 vs INVA: -5.82

Innoviva Return-on-Tangible-Asset Historical Data

The historical data trend for Innoviva's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Return-on-Tangible-Asset Chart

Innoviva Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.03 27.61 22.78 18.46 2.26

Innoviva Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.46 -13.77 0.49 7.83 -17.67

Competitive Comparison of Innoviva's Return-on-Tangible-Asset

For the Biotechnology subindustry, Innoviva's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Innoviva's Return-on-Tangible-Asset falls into.


;
;

Innoviva Return-on-Tangible-Asset Calculation

Innoviva's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=23.392/( (995.267+1074.722)/ 2 )
=23.392/1034.9945
=2.26 %

Innoviva's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-186.336/( (1074.722+1034.527)/ 2 )
=-186.336/1054.6245
=-17.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Innoviva  (NAS:INVA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Innoviva Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Innoviva's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva Business Description

Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Executives
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511